Cue Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(158,245) | $(20,739) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 602 | 200 |
| Stock-based compensation | 23,886 | 2,601 |
| Decrease in the carrying amount of right-of-use-assets | 735 | 1,478 |
| Gain on lease termination | (10) | — |
| Issuance of Ascendant liability-classified pre-funded warrants and top-up share obligation | 20,119 | — |
| Loss on issuance of liability-classified warrants | 87,559 | — |
| Changes in fair value of financial instruments | (24,487) | — |
| Amortization of debt issuance costs | — | 18 |
| Accretion of final payment on term loans | — | 65 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 169 | 413 |
| Prepaid expenses and other current assets | (1,113) | (1,545) |
| Deposits | 1,109 | 458 |
| Foreign withholding tax receivable | — | (1,899) |
| Other payable | 271 | 189 |
| Accounts payable | (201) | 804 |
| Accrued expenses | 15,724 | (1,390) |
| Research and development contract liability | (5,335) | 9,494 |
| Operating lease liability | (729) | (1,550) |
| Other assets | — | (184) |
| Net cash used in operating activities | (39,946) | (11,587) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (121) | (177) |
| Net cash used in investing activities | (121) | (177) |
| Cash flows from financing activities | ||
| Proceeds from ATM offering, net of sales agent commissions and fees | 306 | 752 |
| Proceeds from issuance of warrants and pre-funded warrants, net of transaction costs | 27,548 | 18,046 |
| Repayment of term loans | — | (2,000) |
| Proceeds from exercise of stock options | 815 | — |
| Proceeds from exercise of warrants and pre-funded warrants, net | 1,654 | — |
| Net cash provided by financing activities | 30,323 | 16,798 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (9,744) | 5,034 |
| Cash, cash equivalents, and restricted cash at beginning of period | 27,290 | 22,611 |
| Cash, cash equivalents, and restricted cash at end of period | $17,546 | $27,645 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Cash paid for interest | $— | $157 |
| Reclassification of May 2026 warrants and pre-funded warrants to equity | $(94,186) | $— |
| Reclassification of Ascendant pre-funded warrants to equity | $(13,275) | $— |
| Lease liabilities arising from obtaining right-of-use assets | $— | $2,226 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.